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Background: Laxatives are among the most widely used over-the-counter medications in the United States but
studies examining their potential hazardous side effects are sparse. Associations between laxative use and risk for
fractures and change in bone mineral density [BMD] have not previously been investigated.
Methods: This prospective analysis included 161,808 postmenopausal women (8907 users and 151,497 nonusers of
laxatives) enrolled in the WHI Observational Study and Clinical Trials. Women were recruited from October 1, 1993, to
December 31, 1998, at 40 clinical centers in the United States and were eligible if they were 50 to 79 years old and
were postmenopausal at the time of enrollment. Medication inventories were obtained during in-person interviews at
baseline and at the 3-year follow-up visit on everyone. Data on self-reported falls (≥2), fractures (hip and total fractures)
were used. BMD was determined at baseline and year 3 at 3 of the 40 clinical centers of the WHI.
Results: Age-adjusted rates of hip fractures and total fractures, but not for falls were similar between laxative users and
non-users regardless of duration of laxative use. The multivariate-adjusted hazard ratios for any laxative use were 1.06 (95%
confidence interval [CI], 1.03-1.10) for falls, 1.02 (95% CI, 0.85-1.22) for hip fractures and 1.01 (95% CI, 0.96-1.07) for total
fractures. The BMD levels did not statistically differ between laxative users and nonusers at any skeletal site after 3-years
intake.
Conclusion: These findings support a modest association between laxative use and increase in the risk of falls but not
for fractures. Its use did not decrease bone mineral density levels in postmenopausal women. Maintaining physical
functioning, and providing adequate treatment of comorbidities that predispose individuals for falls should be
considered as first measures to avoid potential negative consequences associated with laxative use.
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Laxatives belong to one of the most frequently sold over-
the-counter pharmacy sales categories in the United States
[1]. In 2011, consumers spent approximately $875 million
on laxative drug products [1]. This easy availability can fa-
cilitate use without indication, long-term use, inappropriate
dosing and even abuse of these medicines [2-4]. Electrolyte* Correspondence: Haring_B@medizin.uni-wuerzburg.de
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reproduction in any medium, provided the orand fluid imbalances have been reported as potential nega-
tive consequences and side-effects of laxative use [2-7].
These medical conditions are known causes of muscle
weakness, lassitude, cardiac arrhythmias, and osteoporosis
that may increase the risk for falls and fractures [8-14]. In
fact, use of a wide range of prescription drugs such as loop
diuretics or antiepileptics have already been shown to be
associated with falls, fractures and even changes in bone
mineral density as these drugs may alter fluid and electro-
lyte metabolism (e.g. hyponatremia, hypocalemia) and even
vitamin D absorption [10,15-19].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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that laxative use increases the risk for falls [2,20-29].
However, these studies were limited by small numbers of
falls, lack of data on important potential confounders
and short follow-up period [20,22,27,29]. Additionally,
although electrolyte and fluid imbalances, vitamin mal-
absorption as well as a history of falls are important risk
factors for changes in bone mineral density and fractures
[9,10,30-39], the effect of laxative use on these bone out-
comes remains to be determined.
Based on current literature laxative users may be char-
acterized by several different groups [4,40,41]. The first
and by far largest group is made up of individuals who
are generally middle aged or older who begin using laxa-
tives when constipated. The second group consists of
individuals suffering from an eating disorder such as an-
orexia or bulimia nervosa. Third, individuals engaged in
certain types of sports training may be inclined to be
users. The fourth group includes surreptitious laxative
abusers who use the drugs to cause factitious diarrhea.
As constipation occurs more frequently in the female
population and it becomes more prevalent with increas-
ing age [42-45], the role of laxative use in postmeno-
pausal women is of particular interest.
Our aim is to evaluate a possible association of laxative
intake with the incidence of falls, total fractures, hip
fractures and change in bone mineral density in post-
menopausal women. Such information may provide
insight into the safety profile and potential hazards of a
widely used medication class and thereby be of high
public health relevance.
Methods
Study population
The study population consisted of 161,808 women en-
rolled in the Women’s Health Initiative (WHI) Observa-
tional Study (OS) (n=93,676) and Clinical Trials (CTs)
(n=68,132). Details of the study population have been
described elsewhere [46-50]. For this analysis, 160,404
women with no prior hip fracture (OS: n=92,789/CT:
n=67,615) were included. Women were recruited from
October 1, 1993, to December 31, 1998, at 40 clinical
centers in the United States and were eligible if they
were 50 to 79 years old and were postmenopausal at the
time of enrollment. In addition to age and menopausal
status, eligibility criteria for the clinical trial (CT) and
observational study (OS) included ability and willingness
to provide written informed consent and an agreement
to reside in the area for at least 3 years after enrollment
[51], [46]. Participants were subsequently followed up
through March 31, 2005, for an average of 7.8 years (OS:
7.6 years /CT: 8 years). Among 160,404 women, 7421
(4.6%) were lost to follow-up (OS: n=4451/ CT: n=2970),
whereas 9709 (6.1%) deceased (OS: n=6146 /CT: n= 3563).OS participants were scheduled for two clinic visits at
baseline and year 3 of follow-up compared to CT partici-
pants who were scheduled for clinic visits at years 1, 3, 6
and 9. To update selected exposures and ascertain medical
outcomes participants in the OS were mailed annual ques-
tionnaires whereas women in the CTs were sent semian-
nual forms to ensure the timely update of medical histories
[46]. All protocols were approved by institutional review
boards at participating institutions.
Exposure assessment
Current medication use was assessed by asking the par-
ticipants to present all containers for medications taken
for 2 weeks prior to clinic visit [46]. Clinic interviewers
then entered each medication into the WHI database,
which assigned drug codes using Medispan software
(First DataBank, Inc., San Bruno, California). For this
analysis, we used baseline information on current laxa-
tive use including label product name, label generic
name, dosage form, strength and duration (WHI Form
44: Current Medications). Duration of use was examined
in three categories (<1 year, 1 to 3 years, or >3years).
Since the medication class of laxatives is a heteroge-
neous entity with various different kinds of pharmaco-
logically active substances and with many commercially
available laxative products consisting of two or more ac-
tive pharmacological compounds, we investigated the
effect of ‘any (compound containing) laxative’ on our
outcomes of interest. We additionally stratified laxatives
by the underlying containing substances into five categor-
ies [‘oral stimulant containing’, ‘fiber containing’, ‘osmotic
containing’, ‘stool softener containing’ and ‘lubricant
containing’ laxative] to potentially gain information on the
distribution of these categories being used and the effects
on our outcomes of interest. However, as we are lacking
information on the exact composition and pharmaco-
logical impact of each compound of the various commer-
cially available mixture products, for analyses these
categories were not mutually exclusive.
Outcome assessment and other covariates
As primary outcome measures, we assessed the inci-
dence of falls and fractures (total and hip fractures) and
change in bone mineral density. Incident falls and frac-
tures were ascertained prospectively using annual (OS)
or semiannual (CT) self-report questionnaires. Fall his-
tory was obtained by asking about the number of times
the participant fell or landed on the ground (excluding
falls owing to sports) in the interval since the last med-
ical history update (WHI Form 33: Medical History). A
participant was identified as having a history of falls if
she reported 2 or more falls per year as previously defined
in epidemiologic studies [15,16,52,53]. In WHI CTs, all
fracture outcomes were verified by central review of
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tures were centrally adjudicated for all women.
Bone mineral density (BMD) at the total hip, posterior-
anterior spine, and total body was measured at baseline
at 3 of the 40 clinical centers of the WHI (Pittsburgh,
Pennsylvania; Birmingham, Alabama; and Phoenix and
Tucson, Arizona) among 10,833 women with dual-energy
x-ray absorptiometry using a Hologic QDR densitometer
(Hologic Inc, Waltham, Massachusetts). We determined
change in BMD by laxative use at these sites from baseline
to year 3. Information on all covariates was assessed
via self-report, clinic interview or by physical measure at
baseline [54-56].
Statistical analysis
The characteristics of women using laxatives at baseline
were compared with nonusers [Table 1]. Differences
between laxative users and nonusers were compared
using χ2 statistics for categorical variables and t-test or
ANOVA, as appropriate, for continuous variables. Clin-
ical outcomes were summarized according to laxative
use and its various subgroups [Table 2]. Age-adjusted in-
cidence rates of falls, total and hip fractures per 1000
person-years were calculated according to duration of
laxative use by direct-adjustment based on the 5-year
age distribution of the total CTs+OS sample (n=161,808)
[Additional file 1: Table S1]. Hazard ratios (HRs) for the
risk of falls (≥2) and total or hip fractures associated
with laxative use at baseline as compared with no laxa-
tive use were obtained by adjusted Cox proportional
hazards analyses using time from enrollment to the first
occurrence of the event as 'time' in the models [Table 3].
Two models were formed for each outcome to examine
the effect of potential confounding [15,16,57,58]. Model
1 was stratified by 10-year age intervals and OS vs. CT
cohorts, and adjusted for linear age, race/ethnicity, and
randomization assignment for WHI-CTs. Model 2A add-
itionally adjusted for BMI, smoking, physical activity,
self-reported health, treated diabetes mellitus, history of
fracture at age ≥55 years, corticosteroid use, physical func-
tion score, number of chronic medical conditions (includ-
ing treated diabetes mellitus, stroke, any cancer, CVD,
arthritis, hypertension, and emphysema), number of psy-
choactive medications (including anxiolytics, hypnotics,
antidepressants, antipsychotics, and antiepileptic agents),
use of HT and bisphosphonates. Model 2B also included
history of falls (≥2). Similarly, we constructed adjusted
hazards ratio of falls and bone outcomes using time-
dependent laxative use from all medication inventories
collected during follow-up time [Additional file 1: Table
S2]. Data on laxative use were updated at year 3 in the
OS, and at years 1, 3, 6 and 9 in the CT. Follow-up time
was censored three years after last medication collection.
Multivariate linear regression methods were constructedto assess the association of baseline BMD for total hip,
total spine and total body levels with any laxative use, as
well as 3-year changes in BMD [Table 4]. For evaluating
the relation of the duration of laxative intake to the inci-
dence of falls and fractures, we used proportional hazards
models to examine the association of different duration of
laxative use (<1 year, 1–3 years, or >3years) with the out-
comes of interest [Table 5]. We also conducted selected
subgroup analyses for associations of laxative use on the
outcomes by age group, current hormone replacement
therapy use, current psychoactive therapy, BMI and his-
tory of fracture [Additional file 1: Table S3]. Finally, to fur-
ther explore laxative intake under randomized trial
conditions we conducted subgroup analyses relating any
laxative use to incidence of fracture and falls in the WHI
Hormone Therapy Trial [Additional file 1: Table S4]. All
analyses were conducted using SAS statistical software
(version 9.2; SAS Institute Inc, Cary, North Carolina).Results
Among the 161,808 women in the WHI OS and CTs,
160,404 had no prior hip fracture at baseline and were in-
cluded in this study; 8907 (5.6%) of study participants
were currently using laxatives at baseline [Table 1]. Of
those, 1603 persons used an oral stimulant containing
laxative, 5372 a fiber containing laxative, 281 an osmotic
containing laxative, 2525 a stool softener containing laxa-
tive and 33 a lubricant containing laxative [Table 2].
Nearly 4000 women (43.7%) had used laxative medication
for more than 3 years, 3091 (34.7%) for 1 to 3 years, and
1924 (21.6%) for less than 1 year [Table 5]. Those using
laxatives at baseline were of older age, had lower BMI,
more likely to have a lower physical functioning or a his-
tory of fractures, more likely to report low or fair health
or osteoporosis, and to be included in the observational
study (WHI-OS) [Table 1]. Concurrent use of psycho-
active medications and hormone replacement therapy was
more common among laxative users. Calcium and Vita-
min D supplementation as well as bisphosphonates and
calcitonin were more often used by laxative users. After
adjustment for age, ethnicity and BMI laxative users
tended to have a higher lumbar spine and total BMD.
Other baseline characteristics were similar.
During 6.4 follow-up years/person in the laxative non-
user group (n=151,497) as compared to 6.1 follow-up
years/person in the user group (n=8907), 50,175 falls
were reported in the non-user and 3484 falls in the user-
group [Table 2]. The age-adjusted rates of falls were
52.84/1000 person-years for non-users and 63.35/1000
person-years for laxative users. Similarly, the rates of hip
fractures were 1.54/1000 and 1.75/1000 and the rates of
total fractures were 20.89/1000 and 23.07/1000 for laxa-
tive non-users and users [Additional file 1: Table S1].
Table 1 Baseline differences between users and non-users
of laxatives
Laxative
user
(N=8907)
Nonuser
of laxatives
(N=151,497)
P-value
Age
< 60 - 51188 (33.8%) < 0.0001
>= 60 6745 (75.7%) 100309 (66.2%)
Race/ethnicity
White 7859 (88.2%) 124468 (82.2%) < 0.0001
Black 630 (7.1%) 13899 (9.2%)
Other 418 (4.7%) 13130 (8.7%)
BMI (kg/m2)
<25 3334 (37.7%) 52350 (34.9%) < 0.0001
25 - <30 3079 (34.8%) 52168 (34.7%)
>=30 2433 (27.5%) 45624 (30.4%)
Smoking
Never 4353 (49.5%) 76367 (51.1%) < 0.0001
Past 3995 (45.4%) 62554 (41.8%)
Current 451 (5.1%) 10581 (7.1%)
> 7 Alcoholic drinks/week
Nondrinker 3885 (43.7%) 63883 (42.3%) 0.0252
No 3972 (44.7%) 69542 (46.1%)
Yes 1026 (11.6%) 17568 (11.6%)
Coffee intake
0 cups a day 3977 (45.1%) 61373 (40.9%) < 0.0001
<= 1 cup a day 1428 (16.2%) 23379 (15.6%)
1-3 cups a day 2567 (29.1%) 47787 (31.9%)
> 4 cups a day 848 (9.6%) 17359 (11.6%)
Diabetes
No 8482 (95.3%) 144679 (95.6%) 0.2068
Yes 418 (4.7%) 6680 (4.4%)
Physical activity (METs) h/wk
0, Inactive 1259 (14.6%) 22956 (15.9%) < 0.0001
< 5 1712 (19.8%) 30445 (21.1%)
5-12 2083 (24.1%) 34366 (23.8%)
>=12 3584 (41.5%) 56535 (39.2%)
Last medical visit
within one year
No 997 (11.5%) 26958 (18.4%) < 0.0001
Yes 7683 (88.5%) 119360 (81.6%)
Fair or poor
self-reported health
No 7738 (87.4%) 137171 (91.1%) < 0.0001
Yes 1119 (12.6%) 13339 (8.9%)
Osteoporosis
No 7881 (89.4%) 138322 (92.7%) < 0.0001
Yes 932 (10.6%) 10972 (7.3%)
Table 1 Baseline differences between users and non-users
of laxatives (Continued)
Physical functioning > 90
No 6190 (70.7%) 92769 (62.4%) < 0.0001
Yes 2567 (29.3%) 55808 (37.6%)
Number of chronic conditionsa
0 1771 (19.9%) 43185 (28.5%) < 0.0001
1 3016 (33.9%) 53641 (35.4%)
2 2393 (26.9%) 34652 (22.9%)
3 1226 (13.8%) 14609 (9.6%)
>= 4 501 (5.6%) 5410 (3.6%)
History of falls
No 7702 (86.5%) 133542 (88.1%) < 0.0001
Yes 1205 (13.5%) 17955 (11.9%)
Fracture on or after age 55
No 5818 (81.9%) 96946 (84.3%) < 0.0001
Yes 1290 (18.1%) 17991 (15.7%)
Hormone therapy use
Never used 3233 (36.3%) 66953 (44.2%) < 0.0001
Past user 1692 (19.0%) 24005 (15.9%)
Current user 3977 (44.7%) 60405 (39.9%)
Bisphosphonates use
No 8679 (97.4%) 148671 (98.1%) < 0.0001
Yes 228 (2.6%) 2824 (1.9%)
Corticosteroid use
No 8813 (98.9%) 150222 (99.2%) 0.0319
Yes 94 (1.1%) 1273 (0.8%)
Calcitonin use
No 8861 (99.5%) 151077 (99.7%) < 0.0001
Yes 46 (0.5%) 418 (0.3%)
Psychoactive drug use
No 7123 (80.0%) 136454 (90.1%) < 0.0001
Yes 1748 (20.0%) 15043 (9.9%)
Total baseline calcium
intake (mg/d)
<400 458 (5.3%) 11502 (7.8%) < 0.0001
400 - <800 1850 (21.4%) 38580 (26.3%)
800 - <1200 2145 (24.8%) 36436 (24.8%)
>= 1200 4202 (48.5%) 60392 (41.1%)
Calcium supplement use
No 2974 (33.4%) 68257 (45.1%) < 0.0001
Yes 5933 (66.6%) 83238 (54.9%)
Total baseline Vitamin D intake (IU/d)
<200 2557 (29.5%) 56042 (38.1%) < 0.0001
200 - <400 1457 (16.8%) 27342 (18.6%)
400 - <600 2440 (28.2%) 35784 (24.4%)
>= 600 2201 (25.4%) 27742 (18.9%)
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Table 1 Baseline differences between users and non-users
of laxatives (Continued)
Vitamin D supplement use
No 3647 (40.9%) 80042 (52.8%) < 0.0001
Yes 5260 (59.1%) 71453 (47.2%)
Baseline total body
bone densityb
1.017 1.014 0.5236
Baseline total body
bone density adjustedc
1.027 1.012 0.0017
Baseline lumbar spine
bone densityb
0.990 0.979 0.1551
Baseline lumbar spine
bone density adjustedc
0.998 0.978 0.0065
Baseline total hip
bone densityb
0.837 0.853 0.0123
Baseline total hip
bone density adjustedc
0.850 0.850 0.9395
Hormone therapy trial
No 7694 (86.4%) 125585 (82.9%) < 0.0001
Yes 1213 (13.6%) 25912 (17.1%)
Dietary modification trial
No 6652 (74.7%) 105272 (69.5%) < 0.0001
Yes 2255 (25.3%) 46225 (30.5%)
Calcium Vitamin D trial
No 7435 (83.5%) 116920 (77.2%) < 0.0001
Yes 1472 (16.5%) 34577 (22.8%)
Observational study
No 3168 (35.6%) 64447 (42.5%) < 0.0001
Yes 5739 (64.4%) 87050 (57.5%)
a Includes treated diabetes mellitus, stroke, any cancer, CVD, arthritis,
hypertension, 2 or more falls, emphysema.
b From subset.
c Adjusted for age, ethnicity, and BMI.
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was found between ‘any laxative use’ and falls (HR, 1.21;
95% CI, 1.17-1.25), and total fractures (HR, 1.07; 95%
CI, 1.01-1.13) at baseline, while the association with hip
fractures was not statistically significant (HR, 1.11; 95%
CI, 0.94-1.32) [Table 3].When stratifying these associa-
tions by the various laxative subgroups, we noted ‘oral
stimulant’, ‘fiber’ and ‘stool softener containing laxatives’
to be significantly associated with the risk of falls. After
full adjustment ‘any laxative use’ (Model 2A: HR, 1.06;
95% CI, 1.03-1.10), ‘fiber containing laxatives’ (Model
2A: HR, 1.06; 95% CI, 1.01-1.11) and ‘stool softener
containing laxatives’ (Model 2A: HR, 1.08; 95% CI, 1.02-
1.15) remained statistically significantly associated with
falls. These results did only marginally change after add-
itional adjustment for history of falls. No significant rela-
tionship between laxative use and the risk for fractures
was found after fully accounting for confounding factors.
To investigate the effects of laxative use over time,we additionally constructed time-dependent models
[Additional file 1: Table S2]. There we continued to find
a significant association between the risk for falls and
‘any laxative use’ (HR, 1.06; 95% CI, 1.02-1.10) and ‘stool
softener containing laxatives’ (HR 1.13; 95% CI, 1.06-
1.21). In contrast to baseline analyses, ‘oral stimulant
containing laxatives’ (HR, 2.04; 95% CI, 1.36-3.07) and
‘stool softener containing laxatives’ (HR, 1.50; 95% CI,
1.09-2.05) remained significantly associated with the
risk for hip fractures even after full adjustment. No rela-
tionship between the risk for total fractures and any
laxative subgroup except for ‘stool softener containing
laxatives’ (HR, 1.12; 95% CI, 1.00-1.25) could be
established in time-dependent analyses.
At baseline, women using laxatives had similar BMD
at the hip level (adjusted mean, 0.85 vs. 0.84 g/cm2)
compared with nonusers. Total body BMD and total
spine BMD differed significantly in users compared with
nonusers (adjusted mean, 1.02 vs. 1.01 g/cm2 and 0.99
vs. 0.98 g/cm2) [Table 4]. Examining the 3-year BMD
change from baseline, we found small statistically non-
significant increases in BMD in all areas of interest,
which may stem from the fact that a high proportion of
women in both groups were part of the active treatment
arms in the WHI-CT involving calcium and vitamin D
supplementation and/or hormone trial (HT).
Any laxative use tended to be associated with an in-
creased hazard for falls in stratified analysis by exposure
duration while no clear trend could be observed for the
risk for hip fractures or total fractures [Table 5]. Because
laxative use may have different effects on various sub-
populations, we additional undertook several subgroup
analyses [28,59,60]. Laxative use was associated with an
increased hazard for total fractures by age in women
older than 65 years (HR, 1.06; 95% CI, 0.99-1.14, inter-
action p-value = 0.05), although no significant inter-
action by age was found for falls and hip fractures.
Psychoactive therapy was associated with a lower risk
for total fractures (HR, 0.91; 95% CI, 0.81-1.03, inter-
action p-value = 0.05), whereas no significant influence
on falls or hip fractures was noted [Additional file 1:
Table S3]. Finally, we found no significant difference in
the prevalence of laxative intake between women receiv-
ing hormone therapy or placebo under WHI Hormone
Therapy Trial settings [Additional file 1: Table S4]. Inter-
action tests for women stratified by trial randomization
did not result in significant differences in risk of falls
and fractures between laxative users and non-users.
Discussion
In this large prospective study of postmenopausal women
with no prior hip fracture, we found a statistically signifi-
cant association of laxative use with the occurrence of falls
(≥2). Laxative use was not associated with an increased
Table 2 Clinical outcomes according to laxative use and drug class
Clinical outcome No Laxative use
(N=151497)
Laxative use
(N=8907)
Oral
stimulant
containing
laxative
(N=1603)
Fiber
containing
laxative
(N=5372)
Osmotic
containing
laxative
(N=281)
Stool softener
containing
laxative
(N=2525)
Lubricant
containing
laxative
(N=33)
Falls (> 2) 50175 (33.9%) 3484 (40.0%) 588 (37.7%) 2040 (38.8%) 106 (39.3%) 1067 (43.3%) 15 (46.9%)
p-yrs 959,729 53,592
Follow-up yrs (SD) / person 6.4 (2.7) 6.1 (2.7)
Hip fracture 1706 (1.1%) 142 (1.6%) 33 (2.1%) 73 (1.4%) 4 (1.4%) 52 (2.1%) 0 (0.0%)
p-yrs 1,171,740 67,909
Follow-up yrs (SD) / person 7.8 (1.6) 7.6 (1.7)
Total fracture 21642 (14.3%) 1476 (16.6%) 255 (15.9%) 852 (15.9%) 48 (17.1%) 449 (17.8%) 6 (18.2%)
p-yrs 1,053,650 61,029
Follow-up yrs (SD) / person 7.2 (2.2) 7.1 (2.2)
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ment for confounding factors. Among laxative users at
baseline, the HR for falls was 1.06, for hip fractures 1.02
and for total fractures 1.01. The CIs indicate that the true
HR for falls may be as low as 1.03 or as high as 1.10, for
hip fractures 0.85 and 1.22 and for total fractures 0.96 andTable 3 Adjusted hazards ratio of fractures and falls by laxati
Model 1
HR (95% CI)*
Mo
p-v
Falls (≥ 2) Any laxative use 1.21 (1.17, 1.25) <
Oral stimulant containing laxative 1.15 (1.06, 1.25)
Fiber containing laxative 1.15 (1.10, 1.20) <
Osmotic containing laxative 1.20 (0.99, 1.46)
Stool softener containing laxative 1.35 (1.27, 1.44) <
Lubricant containing laxative 1.51 (0.91, 2.50)
Hip fracture Any laxative use 1.11 (0.94, 1.32)
Oral stimulant containing laxative 1.62 (1.15, 2.28)
Fiber containing laxative 0.92 (0.73, 1.16)
Osmotic containing laxative 1.06 (0.40, 2.82)
Stool softener containing laxative 1.46 (1.11, 1.93)
Lubricant containing laxative NA***
Total fracture Any laxative use 1.07 (1.01, 1.13)
Oral stimulant containing laxative 1.13 (0.99, 1.27)
Fiber containing laxative 0.99 (0.92, 1.06)
Osmotic containing laxative 1.15 (0.87, 1.53)
Stool softener containing laxative 1.20 (1.09, 1.31)
Lubricant containing laxative 1.29 (0.58, 2.88)
* Adjusted for age, ethnicity, and WHI clinical trial indicators.
** Adjusted for age, ethnicity, BMI, WHI clinical trial indicators, smoking status, phys
55, corticosteroid use, physical function score, number of chronic medical condition
hypertension, and emphysema), number of psychoactive drugs (including antipsych
HRT, and bisphosphonate use, and in Model 2B history of falls (≥2).
*** No hip fractures occurred in this group.1.07 respectively. Using time-dependent analyses laxative
use remained statistically significantly associated with an
increased risk for falls. These results were most likely
driven by a higher number of women starting to take laxa-
tives during follow-up; thus we achieved a higher power
to detect differences between users and non-users.ve use at baseline
del 1
alue*
Model 2A
HR (95% CI)**
Model 2A
p-value**
Model 2B
HR (95% CI)**
Model 2B
p-value**
.0001 1.06 (1.03, 1.10) 0.0006 1.06 (1.03, 1.10) 0.0008
0.0009 0.98 (0.90, 1.07) 0.6162 0.97 (0.89, 1.05) 0.4450
.0001 1.06 (1.01, 1.11) 0.0147 1.05 (1.01, 1.10) 0.0272
0.0577 1.10 (0.90, 1.34) 0.3493 1.10 (0.90, 1.34) 0.3510
.0001 1.08 (1.02, 1.15) 0.0145 1.10 (1.03, 1.17) 0.0036
0.1113 1.10 (0.63, 1.94) 0.7390 1.06 (0.60, 1.87) 0.8377
0.2200 1.02 (0.85, 1.22) 0.8509 1.02 (0.85, 1.22) 0.8426
0.0062 1.31 (0.90, 1.91) 0.1556 1.32 (0.91, 1.93) 0.1444
0.4907 0.86 (0.67, 1.11) 0.2514 0.87 (0.67, 1.11) 0.2552
0.9118 0.98 (0.37, 2.61) 0.9625 1.00 (0.38, 2.68) 0.9942
0.0070 1.26 (0.94, 1.69) 0.1203 1.26 (0.94, 1.69) 0.1273
0.0137 1.01 (0.96, 1.07) 0.6237 1.02 (0.96, 1.07) 0.5511
0.0606 1.04 (0.92, 1.18) 0.5391 1.04 (0.91, 1.18) 0.5725
0.6831 0.97 (0.90, 1.04) 0.4089 0.97 (0.90, 1.04) 0.4004
0.3263 1.10 (0.82, 1.47) 0.5285 1.12 (0.84, 1.49) 0.4517
0.0002 1.05 (0.95, 1.16) 0.3285 1.06 (0.96, 1.17) 0.2331
0.5267 1.29 (0.58, 2.87) 0.5322 1.26 (0.57, 2.81) 0.5665
ical activity, self-reported health, treated diabetes, history of fracture after age
s (including treated diabetes mellitus, stroke, any cancer, CVD, arthritis,
otic, antiepileptic, anxiolytic, hypnotic and antidepressant drug use), use of
Table 4 Three-year changes in mean bone mineral density (BMD) according to laxative use
Laxative Use No Laxative Use
N Mean (SE) * N Mean (SE) * P-value * P-value ** P-value ***
Total hip
Baseline 509 0.842 (0.006) 10791 0.847 (0.001) 0.4170 0.8376 0.8624
Year 3 424 0.847 (0.006) 8916 0.854 (0.001) 0.2767 0.3282 0.3409
Absolute change 422 0.004 (0.002) 8810 0.006 (0.000) 0.3866 0.3734 0.3714
Percent change 422 0.596 (0.201) 8810 0.730 (0.047) 0.5108 0.4856 0.4791
Total spine
Baseline 487 0.991 (0.007) 10456 0.975 (0.002) 0.0339 0.1307 0.1325
Year 3 401 1.010 (0.009) 8653 0.995 (0.002) 0.0836 0.4034 0.3974
Absolute change 400 0.017 (0.002) 8579 0.021 (0.001) 0.2075 0.1396 0.1573
Percent change 400 1.840 (0.257) 8579 2.198 (0.060) 0.1711 0.1324 0.1505
Total body
Baseline 512 1.023 (0.004) 10794 1.011 (0.001) 0.0090 0.0209 0.0234
Year 3 424 1.033 (0.005) 8891 1.023 (0.001) 0.0692 0.1754 0.1854
Absolute change 423 0.012 (0.002) 8796 0.011 (0.000) 0.6686 0.9132 0.8580
Percent change 423 1.236 (0.181) 8796 1.150 (0.043) 0.6422 0.8545 0.7946
* Adjusted for age, ethnicity, and WHI clinical trial indicators.
** Adjusted for age, ethnicity, BMI, WHI clinical trial indicators, smoking status, physical activity, self-reported health, treated diabetes, history of fracture after age
55, corticosteroid use, physical function score, number of chronic medical conditions (including treated diabetes mellitus, stroke, any cancer, CVD, arthritis,
hypertension, and emphysema), number of psychoactive drugs (including antipsychotic, antiepileptic, anxiolytic, hypnotic and antidepressant drug use), use of
HRT, and bisphosphonate use.
*** Adjusted as in (**) with the addition of history of falls (≥ 2).
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indication as having partly influenced our results. Longer
duration of laxative use did not show a statistically signifi-
cant association with the risk for hip fractures or total
fractures, while a positive relationship for falls could be
observed.
Several intrinsic and extrinsic effects of laxatives have
been associated with their use providing potentialTable 5 Adjusted hazards ratio of fractures and falls by
any laxative use duration
Any
laxative
use
N HR (95% CI)**
Falls (>2) Hip fracture Total fracture
Nonuser 151,497 1 1 1
< 1 year 1924 1.11 (1.04, 1.74) 1.17 (0.89, 1.55) 1.06 (0.97, 1.16)
1-3 years 3091 1.07 (0.99, 1.15) 1.02 (0.69, 1.50) 1.03 (0.92, 1.15)
> 3 years 3892 1.00 (0.95, 1.06) 0.90 (0.68, 1.19) 0.97 (0.89, 1.05)
p-value
for linear
trend
0.0458 0.9553 0.9996
** Adjusted for age, ethnicity, BMI, WHI clinical trial indicators, smoking status,
physical activity, self-reported health, treated diabetes, history of fracture after
age 55, corticosteroid use, physical function score, number of chronic medical
conditions (including treated diabetes mellitus, stroke, any cancer, CVD,
arthritis, hypertension, 2 or more falls and emphysema), number of
psychoactive drugs (including antipsychotic, antiepileptic, anxiolytic, hypnotic
and antidepressant drug use), use of HRT, and bisphosphonate use.mechanisms for an altered risk for falls and bone out-
comes [2,5,9,25,28,61]. Extrinsically, laxatives can in-
crease the urgency to void with resulting higher risk of
falling. Intrinsically, laxatives can lead to diarrhoea with
associated electrolyte and fluid imbalances. Potassium is
the main electrolyte being lost followed by reductions in
sodium and chloride. Generalized muscle weakness,
lassitude and cardiac arrhythmias may be a direct conse-
quence of electrolyte disturbances resulting in an in-
creased risk for falls and bone outcomes [8-14,32,35-38].
Most recent reports have linked electrolyte imbal-
ances such as mild hyponatremia to osteoporosis and
fracture risk [9-11,30,61-63]. Additionally, laxatives
have also been described to irritate bowel functioning
and bowel disturbances in the colon and small bowl
[2,3,28]. Fat-soluble vitamin malabsorption secondary
to these types of laxative induced side effects of small
intestine damage may further predispose for falls, frac-
tures and BMD loss [13,14,32-35,37]. Indeed, prior
epidemiological studies have shown that laxative use is
associated with an increased risk for falls [2,20-28].
One of the first was the St. Louis OASIS study in
which laxative use was found to be an important risk
factor for multiple falls in elderly people living in the
community (OR, 2.14; 95% CI, 1.02-4.49) [59]. Other
cross-sectionally designed studies confirmed this
positive association [22,23,27]. Observational studies
examining medications and chronic diseases with one year
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1.09 (95% CI, 0.86-1.38) and 2.51 (95% CI, 1.50-4.22) with
laxative use [22,23,25,26,29]. A recent meta-analysis sum-
marizing the risks for falls related to laxatives elderly indi-
viduals resulted in an OR 2.03 (95% CI, 1.52-2.72) [28].
Nevertheless, external validity of many included studies
may be limited as the mean age of the study population
was above 80 years old [20,22,27,29] with a small number
of participants, events and short follow-up [20,22]. Last,
data on fracture risk or change in BMD were not assessed
even though a history of falls is an independent risk factor
for fractures [39].
In contrast to previously published findings [28,59],
our results indicate a modest association between laxa-
tive use and the occurrence of falls, whereas we found
no relationship between laxative use and fractures. Fur-
thermore, although baseline total body bone density and
total lumbar spine density varied between laxative users
or non-users, three-year changes in BMD did not show
any significant differences between both groups for all
BMD areas. In particular, we did not observe differences
in total hip bone density between laxative users or not
users. These findings are surprising given the different
baseline characteristics of laxative users and non-users
suggesting that laxative users have a higher number of
chronic conditions, lower physical functioning and are
of older age, factors known to influence the risk for falls,
fractures and changes in BMD [26,64,65]. It may be
explained by various levels of calcium and vitamin D in-
take between the two groups. Nevertheless, given our
hypothesis that laxative intake may potentially cause
electrolyte imbalances, vitamin D malabsorption or even
small intestine mucosal damage, we expected a strong
relationship between falls and laxative use and an in-
creased risk for fractures and BMD reductions. To fur-
ther investigate the association of laxative use with the
incidence of falls and fractures when used concomitantly
with certain medications (psychoactive drugs, hormone
therapy), in certain age groups, with different BMI levels
or history of fracture, we conducted a subgroup analysis.
We found a slightly higher risk for falls in laxative users
being of older age (>65 y), while current psychoactive
therapy, BMI, history of fracture had no negative effect.
Moreover, we noted a higher risk for falls in laxative
users under current hormone treatment in the total
study population (WHI OS and CTs) which we and
others did not continue to observe in a hormone trial
setting [66]. On the other hand, older women using laxa-
tives showed a significant risk for total fractures despite
similar BMD levels. Finally, concomitant use of psycho-
active agents did not increase the risk for hip and total
fractures in our study population.
The strengths of our analysis include the sample size of
our study population, the large number of complete follow-up and the structured availability of several confounding
factors. Nonetheless, our study also exhibits several limita-
tions. Among those, first the relative low prevalence of long
time laxative use and the missing data on dosing may limit
the validity of this study. Also, since many commercially
available laxatives are mixture products consisting of two
or more pharmacologically active substances, our analyses
on the various categories of laxatives are limited due to
missing information on the exact composition of these
products. Second, laxative intake as well as incident falls
and fractures were ascertained via self-report. Hence, we
cannot exclude information bias. However, since laxative
intake is likely to be assumed to be underreported, the ac-
tual effects may be underestimated. Third, even though a
wide range of confounding factors was considered in the
analysis, residual confounding cannot be excluded. Our re-
sults may be partly confounded by indication for which we
controlled by measures of restriction, stratification and ex-
tensive multivariate adjustment. Additionally, even though
this study was designed prospectively, reverse causation
may have influenced our results. Last, as our study popula-
tion consisted of postmenopausal women, generalizability
may be limited and further research in other study popula-
tions is warranted.
Conclusions
Laxative users are characterized by older age, lower physical
functioning, more comorbidities and higher concurrent use
of psychoactive medications and hormone replacement
therapy. Our findings support an association between any
laxative use and increased risk for falls but not with total
fracture risk or hip fracture risk. A relationship of laxative
use with changes in BMD over time was not demonstrated,
but calcium and vitamin D were more often supplemented
by laxative users. Bisphosphonate and calcitonin use was
more likely in this group as well. Thus, questions remain
regarding the influence on bone health and potential risks
associated with long-term laxative use. Given the low cost,
widespread use and over-the-counter availability it appears
prudent to periodically reevaluate laxative use. Maintaining
physical functioning, and providing adequate treatment of
comorbidities that predispose individuals for falls should be
considered as first measures to avoid potential negative
consequences associated with laxative use.
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